Thoughts of self-harm, suicide, and inadequacy, social comparison, and medication-only management have been on the rise for many years and have dramatically increased following the COVID-19 pandemic.
Our Focus
Mind Therapeutics conducts psilocybin micro dose and trip dose clinical trials with our advanced biotechnology data collection process.
Mind Therapeutics compares the objective data to subjective psychological measurements to analyze patterns and metrics of clinical response to psilocybin.
Patients will wear devices that gather brain and chemical responses to psilocybin.
The physiological reactions will be coupled with psychological measurements for a full picture of how the dosing impacts the person.
We see the prevalence and expansion of these mental health disorders globally:
Our Clinical Trials
Mind Therapeutics will examine delivery methods and micro and trip psilocybin ratios regarding health and disease management.
We will collect brainwave biometrics data with advanced biotechnology devices like QEEG scans and a continuous body monitor.
These devices pair with an app and relay important information about how the body reacts to dosing.
We will compare the objective data to analyze patterns and metrics of clinical response to psilocybin.
We want patients to achieve long-term results and regain control over their mental health.
Our Goal
We hope to establish new treatments through our extensive clinical trials and improve wellness and performance of the mind.
Join Our study
We at Mind Therapeutics are united by our commitment to improve patient experience and healing in mental health care.
Below is a submission link to join our study for those who are experiencing Anxiety, Depression,PTSD and Addiction and looking for alternative, experimental therapies.
Investors
Join us by investing in our journey to improve mental
health and happiness. Sign up for regular updates,
press releases, and announcements that are
delivered right to your inbox.
Newsletter
Join our Healing Community by signing up for a newsletter to receive the latest news and updates of our work and discoveries.